A citation-based method for searching scientific literature

Paul K Lovelock, Amanda B Spurdle, Myth T S Mok, Daniel J Farrugia, Sunil R Lakhani, Sue Healey, Stephen Arnold, Daniel Buchanan, Fergus J Couch, Beric R Henderson, David E Goldgar, Sean V Tavtigian, Georgia Chenevix-Trench, Melissa A Brown. Breast Cancer Res 2007
Times Cited: 48







List of co-cited articles
344 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.
Douglas F Easton, Amie M Deffenbaugh, Dmitry Pruss, Cynthia Frye, Richard J Wenstrup, Kristina Allen-Brady, Sean V Tavtigian, Alvaro N A Monteiro, Edwin S Iversen, Fergus J Couch,[...]. Am J Hum Genet 2007
309
56

Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2.
David E Goldgar, Douglas F Easton, Amie M Deffenbaugh, Alvaro N A Monteiro, Sean V Tavtigian, Fergus J Couch. Am J Hum Genet 2004
274
47

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.
Sharon E Plon, Diana M Eccles, Douglas Easton, William D Foulkes, Maurizio Genuardi, Marc S Greenblatt, Frans B L Hogervorst, Nicoline Hoogerbrugge, Amanda B Spurdle, Sean V Tavtigian. Hum Mutat 2008
542
37

Genetic evidence and integration of various data sources for classifying uncertain variants into a single model.
David E Goldgar, Douglas F Easton, Graham B Byrnes, Amanda B Spurdle, Edwin S Iversen, Marc S Greenblatt. Hum Mutat 2008
131
35

Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
Georgia Chenevix-Trench, Sue Healey, Sunil Lakhani, Paul Waring, Margaret Cummings, Ross Brinkworth, Amie M Deffenbaugh, Lynn Anne Burbidge, Dmitry Pruss, Thad Judkins,[...]. Cancer Res 2006
131
31


Functional assays for classification of BRCA2 variants of uncertain significance.
Daniel J Farrugia, Mukesh K Agarwal, Vernon S Pankratz, Amie M Deffenbaugh, Dmitry Pruss, Cynthia Frye, Linda Wadum, Kiley Johnson, Jennifer Mentlick, Sean V Tavtigian,[...]. Cancer Res 2008
88
29

Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.
J Vallon-Christersson, C Cayanan, K Haraldsson, N Loman, J T Bergthorsson, K Brøndum-Nielsen, A M Gerdes, P Møller, U Kristoffersson, H Olsson,[...]. Hum Mol Genet 2001
131
27

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
25

Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.
Kangjian Wu, Shannon R Hinson, Akihiro Ohashi, Daniel Farrugia, Patricia Wendt, Sean V Tavtigian, Amie Deffenbaugh, David Goldgar, Fergus J Couch. Cancer Res 2005
101
22

Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
Megan S Lee, Ruth Green, Sylvia M Marsillac, Nicolas Coquelle, R Scott Williams, Telford Yeung, Desmond Foo, D Duong Hau, Ben Hui, Alvaro N A Monteiro,[...]. Cancer Res 2010
98
22

Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
Amanda B Spurdle, Sunil R Lakhani, Sue Healey, Suzanne Parry, Leonard M Da Silva, Ross Brinkworth, John L Hopper, Melissa A Brown, Davit Babikyan, Georgia Chenevix-Trench,[...]. J Clin Oncol 2008
61
20

ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
Amanda B Spurdle, Sue Healey, Andrew Devereau, Frans B L Hogervorst, Alvaro N A Monteiro, Katherine L Nathanson, Paolo Radice, Dominique Stoppa-Lyonnet, Sean Tavtigian, Barbara Wappenschmidt,[...]. Hum Mutat 2012
181
20

BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.
Amanda B Spurdle, Phillip J Whiley, Bryony Thompson, Bingjian Feng, Sue Healey, Melissa A Brown, Christopher Pettigrew, Christi J Van Asperen, Margreet G E M Ausems, Anna A Kattentidt-Mouravieva,[...]. J Med Genet 2012
66
20

Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
S V Tavtigian, A M Deffenbaugh, L Yin, T Judkins, T Scholl, P B Samollow, D de Silva, A Zharkikh, A Thomas. J Med Genet 2006
473
18

Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
Marcelo A Carvalho, Sylvia M Marsillac, Rachel Karchin, Siranoush Manoukian, Scott Grist, Ramona F Swaby, Turan P Urmenyi, Edson Rondinelli, Rosane Silva, Luis Gayol,[...]. Cancer Res 2007
91
18

Classification of BRCA1 missense variants of unknown clinical significance.
C M Phelan, V Dapic, B Tice, R Favis, E Kwan, F Barany, S Manoukian, P Radice, R B van der Luijt, B P M van Nesselrooij,[...]. J Med Genet 2005
75
18

A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example.
Leila Mohammadi, Maaike P Vreeswijk, Rogier Oldenburg, Ans van den Ouweland, Jan C Oosterwijk, Annemarie H van der Hout, Nicoline Hoogerbrugge, Marjolijn Ligtenberg, Margreet G Ausems, Rob B van der Luijt,[...]. BMC Cancer 2009
44
20

A guide for functional analysis of BRCA1 variants of uncertain significance.
Gaël A Millot, Marcelo A Carvalho, Sandrine M Caputo, Maaike P G Vreeswijk, Melissa A Brown, Michelle Webb, Etienne Rouleau, Susan L Neuhausen, Thomas v O Hansen, Alvaro Galli,[...]. Hum Mutat 2012
84
18

Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.
P K Lovelock, S Healey, W Au, E Y M Sum, A Tesoriero, E M Wong, S Hinson, R Brinkworth, A Bekessy, O Diez,[...]. J Med Genet 2006
34
23

Prediction and assessment of splicing alterations: implications for clinical testing.
Amanda B Spurdle, Fergus J Couch, Frans B L Hogervorst, Paolo Radice, Olga M Sinilnikova. Hum Mutat 2008
90
16

Evidence for a transcriptional activation function of BRCA1 C-terminal region.
A N Monteiro, A August, H Hanafusa. Proc Natl Acad Sci U S A 1996
394
16

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
16

A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
Encarna B Gómez García, Jan C Oosterwijk, Maarten Timmermans, Christi J van Asperen, Frans B L Hogervorst, Nicoline Hoogerbrugge, Rogier Oldenburg, Senno Verhoef, Charlotte J Dommering, Margreet G E M Ausems,[...]. Breast Cancer Res 2009
41
19

Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity.
Logan C Walker, Phillip J Whiley, Fergus J Couch, Daniel J Farrugia, Sue Healey, Diana M Eccles, Feng Lin, Samantha A Butler, Sheila A Goff, Bryony A Thompson,[...]. Hum Mutat 2010
46
17

A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
Noralane M Lindor, Lucia Guidugli, Xianshu Wang, Maxime P Vallée, Alvaro N A Monteiro, Sean Tavtigian, David E Goldgar, Fergus J Couch. Hum Mutat 2012
139
16

A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.
Lucia Guidugli, Vernon S Pankratz, Namit Singh, James Thompson, Catherine A Erding, Christoph Engel, Rita Schmutzler, Susan Domchek, Katherine Nathanson, Paolo Radice,[...]. Cancer Res 2013
71
16

Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.
A Osorio, R L Milne, E Honrado, A Barroso, O Diez, R Salazar, M de la Hoya, A Vega, J Benítez. Hum Mutat 2007
35
20

Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.
V Abkevich, A Zharkikh, A M Deffenbaugh, D Frank, Y Chen, D Shattuck, M H Skolnick, A Gutin, S V Tavtigian. J Med Genet 2004
124
14

Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer.
Julie A Clapperton, Isaac A Manke, Drew M Lowery, Timmy Ho, Lesley F Haire, Michael B Yaffe, Stephen J Smerdon. Nat Struct Mol Biol 2004
174
14

Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1.
R Scott Williams, Megan S Lee, D Duong Hau, J N Mark Glover. Nat Struct Mol Biol 2004
174
14

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
14

A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Peter Bouwman, Hanneke van der Gulden, Ingrid van der Heijden, Rinske Drost, Christiaan N Klijn, Pramudita Prasetyanti, Mark Pieterse, Ellen Wientjens, Jost Seibler, Frans B L Hogervorst,[...]. Cancer Discov 2013
78
14


A full-likelihood method for the evaluation of causality of sequence variants from family data.
Deborah Thompson, Douglas F Easton, David E Goldgar. Am J Hum Genet 2003
87
12


In silico analysis of missense substitutions using sequence-alignment based methods.
Sean V Tavtigian, Marc S Greenblatt, Fabienne Lesueur, Graham B Byrnes. Hum Mutat 2008
144
12

BRCA1 and BRCA2: 1994 and beyond.
Steven A Narod, William D Foulkes. Nat Rev Cancer 2004
590
12

Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios.
Rachel Karchin, Mukesh Agarwal, Andrej Sali, Fergus Couch, Mary S Beattie. Cancer Inform 2008
37
16

Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs.
Maaike P G Vreeswijk, Jaennelle N Kraan, Heleen M van der Klift, Geraldine R Vink, Cees J Cornelisse, Juul T Wijnen, Egbert Bakker, Christi J van Asperen, Peter Devilee. Hum Mutat 2009
76
12

Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155.
Suhwan Chang, Rui-Hong Wang, Keiko Akagi, Kyung-Ae Kim, Betty K Martin, Luca Cavallone, Diana C Haines, Mark Basik, Phuong Mai, Elizabeth Poggi,[...]. Nat Med 2011
156
12

Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs.
Maxime P Vallée, Tiana C Francy, Megan K Judkins, Davit Babikyan, Fabienne Lesueur, Amanda Gammon, David E Goldgar, Fergus J Couch, Sean V Tavtigian. Hum Mutat 2012
53
12

BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.
Reena Shakya, Latarsha J Reid, Colleen R Reczek, Francesca Cole, Dieter Egli, Chyuan-Sheng Lin, Dirk G deRooij, Steffen Hirsch, Kandasamy Ravi, James B Hicks,[...]. Science 2011
160
12

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
12

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
Sunil R Lakhani, Jorge S Reis-Filho, Laura Fulford, Frederique Penault-Llorca, Marc van der Vijver, Suzanne Parry, Timothy Bishop, Javier Benitez, Carmen Rivas, Yves-Jean Bignon,[...]. Clin Cancer Res 2005
444
10

Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations.
Thaddeus Judkins, Brant C Hendrickson, Amie M Deffenbaugh, Kristilyn Eliason, Benoît Leclair, Michael J Norton, Brian E Ward, Dmitri Pruss, Thomas Scholl. Cancer Res 2005
49
10

Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.
Nebojsa Mirkovic, Marc A Marti-Renom, Barbara L Weber, Andrej Sali, Alvaro N A Monteiro. Cancer Res 2004
83
10

ESEfinder: A web resource to identify exonic splicing enhancers.
Luca Cartegni, Jinhua Wang, Zhengwei Zhu, Michael Q Zhang, Adrian R Krainer. Nucleic Acids Res 2003
10

Assessment of functional effects of unclassified genetic variants.
Fergus J Couch, Lene Juel Rasmussen, Robert Hofstra, Alvaro N A Monteiro, Marc S Greenblatt, Niels de Wind. Hum Mutat 2008
80
10

Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
Marc Tischkowitz, Nancy Hamel, Marcelo A Carvalho, Gabriel Birrane, Aditi Soni, Erik H van Beers, Simon A Joosse, Nora Wong, David Novak, Louise A Quenneville,[...]. Eur J Hum Genet 2008
33
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.